#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small intestine adenocarcinoma Lymphangiosarcoma Chronic graft versus host disease Antiphospholipid syndrome Angiosarcoma recurrent Penile squamous cell carcinoma Squamous cell carcinoma of head and neck Thrombotic thrombocytopenic purpura Cutaneous T-cell lymphoma stage II Depression Cholangitis sclerosing Metastases to central nervous system Fms-like tyrosine kinase 3 positive Human papilloma virus immunisation Mucous membrane pemphigoid More trials…

    Learn about Rare Diseases

    Crigler-Najjar syndrome – Diagnostics Richter’s syndrome – Trials in Disease Castleman’s disease – Life with Disease Gastrointestinal stromal tumour – Treatment Glomerulonephritis rapidly progressive – Life with Disease VEXAS syndrome – Life with Disease Anaplastic thyroid cancer – Trials in Disease Nephrotic syndrome – Treatment Lennox-Gastaut syndrome – Diagnostics Angiosarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TUVATEXIB Acp-204 Tartrate Avibactam Sodium Guanfacine Dalteparin Sodium Mk-1088 Vafidemstat Taldefgrobep Alfa Mps-216 Lenvatinib Sotalol Vatiquinone Padeliporfin Mepolizumab Kbp-336 Pemetrexed Tin816 Sotatercept TTX-381 TROFOLASTAT More therapies…

    Learn about Your Condition

    Mucous membrane pemphigoid Chordoma Soft tissue sarcoma Overweight Thermal burn Primary amyloidosis Chondroplasty Intestinal obstruction Ulcerative keratitis Leiomyosarcoma recurrent Systemic scleroderma Food allergy Gouty arthritis Nodal osteoarthritis Femoral neck fracture More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neuroendocrine carcinoma

  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Carboplatin
    • Etoposide
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    Austria Belgium Czechia Denmark Finland France +8

  • Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    • Small cell lung cancer metastatic
    Investigated Drugs:
    • Tarlatamab
    France Germany

  • Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    Spain

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Copper (64Cu) Chloride
    • Dotatate
    • Fludeoxyglucose (18F)
    Denmark

  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Pyruvic Acid
    • Fludeoxyglucose (18F)
    Denmark

  • Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Recruiting

    2 1 1
    Investigated Drugs:
    • Bi 764532
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    Belgium Bulgaria France Germany Italy Poland +2
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!